A Phase 3, Multicenter Study to Assess the Long Term Safety and Tolerability of ALKS 3831 in Subjects With Schizophrenia
Phase of Trial: Phase III
Latest Information Update: 02 Aug 2017
At a glance
- Drugs Olanzapine/samidorphan (Primary)
- Indications Schizophrenia
- Focus Adverse reactions
- Sponsors Alkermes plc
- 04 May 2017 This trial was completed in Slovakia, according to European Clinical Trials Database.
- 26 Feb 2016 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
- 15 Feb 2016 New trial record